By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Pfizer Joins Microbiome Movement with Second Genome
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > Pfizer Joins Microbiome Movement with Second Genome
BusinessMedical Innovations

Pfizer Joins Microbiome Movement with Second Genome

Deanna Pogorelc
Deanna Pogorelc
Share
3 Min Read
SHARE

gut bacteria prebioticsFirst published on MedCityNews.com. Scientific understanding of the microbiome – the ecosystem of bacteria in the gut – has matured to the point where the pharmaceutical industry recognizes it as a critical part of drug discovery, says Peter DiLaura, CEO of Second Genome.

gut bacteria prebioticsFirst published on MedCityNews.com. Scientific understanding of the microbiome – the ecosystem of bacteria in the gut – has matured to the point where the pharmaceutical industry recognizes it as a critical part of drug discovery, says Peter DiLaura, CEO of Second Genome.

“The microbiome certainly is not total picture of disease, but there’s now recognition that you can’t ignore it if you’re trying to understand complex chronic diseases,” he said.

Second Genome has just struck its second Big Pharma deal to explore the role of microbes in disease, and to identify potential new drug targets. Last summer, it paired up with Janssen Biotech to study ulcerative colitis. Now it’s working with Pfizer on what DiLaura called the largest microbiome study in humans to date.

More Read

ysvc9usjre2loa_3zjo17w
Hospital Cost Reduction Efforts See Hope at the End of New Platform
Florida’s Problem: Cutting Medicaid May Cost the State More
Prescription Drugs in the United States [INFOGRAPHIC]
Using Social Media, Digital Resources and Health 2.0
Be Inspired: 3 Ways to Originate the Content Your Patients Want

In an effort to better understand the relationship between the microbiome, obesity and metabolic disorders, they’ll study about 900 obese individuals selected by a team at Massachussets General Hospital over 12 months. In addition to looking at their microbiomes, they’ll also look at their genome and other components of the host biology to understand how interactions between the gut microbes of obese and non-obese people differ.

A correlation between microbes and metabolic disease has emerged in several recent studies, including studies of microbiome transplants in mice. Now that the correlation has been established, DiLaura said, it’s time to untangle the functional relationships that microbes have with the host, to determine how they could best be modulated to prevent or correct a diseased state.

For Pfizer, that knowledge could lead to better drugs for obesity and diabetes.

“Understanding the complex set of interactions between the gut microbes in obese and non-obese individuals is critical to our research in metabolic disease, a key area of focus at Pfizer,” said Barbara Sosnowski, vice President of external R&D innovation at Pfizer, in a statement.

The terms of the deal were not disclosed.

San Bruno, California-based Second Genome has raised more than $11 million in funding since its inception in 2009.

TAGGED:obesityPfizerpharmaSecond Genome
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

evan falchuk discusses healthcare
BusinessHealth ReformPolicy & LawPublic Health

Interview with Evan Falchuk, Candidate for Governor of Massachusetts

March 6, 2014
Healthcare financing
BusinessFinance

How Hospitals can Obtain Financing in a Challenging Environment

May 11, 2016
Processed with VSCOcam with acg preset
BusinessHealth ReformNewsPolicy & Law

All Payor Claims Databases: ERISA Pre-emption and the Tragedy of the Commons

March 8, 2016

Crowd-Sourcing in Clinical Development

July 25, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?